市場調査レポート
商品コード
1541067
自己免疫疾患診断市場レポート:製品タイプ、疾患タイプ、検査タイプ、エンドユーザー、地域別、2024~2032年Autoimmune Disease Diagnosis Market Report by Product Type, Disease Type, Test Type, End-User, and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
自己免疫疾患診断市場レポート:製品タイプ、疾患タイプ、検査タイプ、エンドユーザー、地域別、2024~2032年 |
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2~3営業日
|
世界の自己免疫疾患診断市場規模は2023年に39億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに64億米ドルに達し、2024~2032年の成長率(CAGR)は5.4%になると予測しています。自己免疫疾患の罹患率の増加、保険契約の売上高増加、EMRの利用拡大などが市場を牽引する主要要因です。
自己免疫疾患は、免疫系が身体の細胞、組織、臓器を攻撃する疾患群です。全身性エリテマトーデス(SLE)、多発性硬化症、関節リウマチ、i型糖尿病など、さまざまな病状によって引き起こされます。倦怠感、関節痛やこわばり、皮疹、発熱、消化不良などを伴います。また、臓器や組織に損傷を与え、呼吸困難、臓器不全、あるいは死亡などの重篤な症状を引き起こすこともあります。詳しい病歴の聴取、身体診察、特異的抗体を検出するための血液検査、損傷や炎症を探すための画像検査、罹患した組織を顕微鏡で調べるための生検など、様々なアプローチを組み合わせて診断することができます。
自己免疫疾患の患者数の急増と、そのような病状を発症しやすい高齢化人口の増加は、世界中で自己免疫疾患診断の需要を促進する主要要因の一つです。さらに、自己免疫疾患、その症状、診断、治療オプションの容易な利用可能性に関する意識の高まりが、市場の成長を後押ししています。さらに、自己免疫疾患の診断や治療に対する経済的支援を提供し、医療費全体を削減する健康保険の導入が拡大していることも、市場にプラスの影響を与えています。これとは別に、自己免疫疾患の研究や新しい治療法を開発するための研究開発(R&D)プロジェクトに資金を提供している国もあります。また、自己免疫疾患の診断方法の改善を目的としたプログラムにも投資しています。そのほかにも、誰もが利用しやすい質の高い医療施設を提供するための取り組みも行っています。このことは、診断技術の著しい向上と相まって、市場の成長を強化しています。さらに、医療従事者がより包括的な患者情報にアクセスできるようになり、自己免疫疾患診断の正確性と迅速性を向上させるために電子カルテ(EMR)の使用が増加しています。このことは、遠隔医療の採用の増加とともに、遠隔自己免疫疾患診断・モニタリング技術の需要を喚起しています。これに加えて、従来の診断手順と比較して苦痛の少ない非侵襲的診断に対する需要の高まりが、市場に明るい展望をもたらしています。
The global autoimmune disease diagnosis market size reached US$ 3.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.4% during 2024-2032. The increasing incidences of autoimmune diseases, rising sales of insurance policies, and the growing use of EMRs represent some of the key factors driving the market.
An autoimmune disease is a group of disorders wherein the immune system attacks the cells, tissues, and organs of the body. It can be caused by different medical conditions, such as systemic lupus erythematosus (SLE), multiple sclerosis, rheumatoid arthritis, and type I diabetes. It is associated with fatigue, joint pain and stiffness, skin rashes, fever, and digestive problems. It can also cause damage to organs and tissues, which leads to more severe symptoms like difficulty breathing, organ failure, or even death. It can be diagnosed via a combination of various approaches, such as taking a detailed medical history, performing a physical examination, blood tests to detect specific antibodies, imaging tests to look for damage or inflammation, and a biopsy to examine the affected tissue under a microscope.
The surging incidences of autoimmune diseases among individuals and the increasing aging population that are susceptible to develop such medical conditions represent one of the major factors driving the demand for autoimmune disease diagnosis around the world. Moreover, the rising awareness about autoimmune disease, its symptoms, diagnosis, and the easy availability of the treatment options is favoring the growth of the market. In addition, the growing implementation of health insurance policies that offer financial assistance for autoimmune disease diagnosis or treatment and reduce overall medical expenses is influencing the market positively. Apart from this, governing authorities of several countries are financing research and development (R&D) projects to study autoimmune diseases and develop new treatments. They are also investing in programs that aim to develop improved diagnostic methods for these medical disorders. Besides this, they are undertaking initiatives to offer quality healthcare facilities that are accessible to all. This, coupled with significant improvements in the diagnostic technologies, is strengthening the growth of the market. Furthermore, there is an increase in the use of electronic medical records (EMRs) to improve the accuracy and speed of autoimmune disease diagnosis as healthcare professionals have access to more comprehensive patient information. This, along with the rising adoption of telemedicine is catalyzing the demand for remote autoimmune disease diagnosis and monitoring technologies. Besides this, the growing demand for non invasive diagnosis, which is less painful as compared to traditional diagnostic procedures, is creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global autoimmune disease diagnosis market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product type, disease type, test type, and end-user.
Consumables and Assay Kits
Instruments
The report has provided a detailed breakup and analysis of the autoimmune disease diagnosis market based on the product type. This includes consumables and assay kits, and instruments. According to the report, consumables and assay kits represented the largest segment.
Systemic Autoimmune Disease
Rheumatoid Arthritis
Psoriasis
Systemic Lupus Erythematosus (SLE)
Multiple Sclerosis
Others
Localized Autoimmune Disease
Inflammatory Bowel Disease
Type 1 Diabetes
Thyroid
Others
A detailed breakup and analysis of the autoimmune disease diagnosis market based on the disease type has also been provided in the report. This includes systemic autoimmune disease (rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), multiple sclerosis, and others) and localized autoimmune disease (inflammatory bowel disease, type 1 diabetes, thyroid, and others). According to the report, localized autoimmune disease (inflammatory bowel disease, type 1 diabetes, thyroid, and others) accounted for the largest market share.
Routine Laboratory Tests
Inflammatory Markers
Autoantibodies and Immunologic Tests
Others
The report has provided a detailed breakup and analysis of the autoimmune disease diagnosis market based on the test type. This includes routine laboratory tests, inflammatory markers, autoantibodies and immunologic tests, and others. According to the report, routine laboratory tests represented the largest segment.
Clinical Laboratories
Hospitals
Others
A detailed breakup and analysis of the autoimmune disease diagnosis market based on the end-user has also been provided in the report. This includes clinical laboratories, hospitals, and others. According to the report, clinical laboratories accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for autoimmune disease diagnosis. Some of the factors driving the North America autoimmune disease diagnosis market included the easy availability of treatments, technological advancements, extensive research and development (R&D) projects, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global autoimmune disease diagnosis market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, AESKU.GROUP, Danaher Corp., bioMerieux SA, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Hemagen Diagnostics, Inc., Inova Diagnostics, Inc., Myriad Genetics, Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, SQI Diagnostics, Thermo Fisher Scientific Inc., Trinity Biotech plc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.